Literature DB >> 28457754

Investigation of the structural requirements of K-Ras(G12D) selective inhibitory peptide KRpep-2d using alanine scans and cysteine bridging.

Ayumu Niida1, Shigekazu Sasaki2, Kazuko Yonemori2, Tomoya Sameshima2, Masahiro Yaguchi2, Taiji Asami2, Kotaro Sakamoto3, Masahiro Kamaura2.   

Abstract

A structure-activity relationship study of a K-Ras(G12D) selective inhibitory cyclic peptide, KRpep-2d was performed. Alanine scanning of KRpep-2d focusing on the cyclic moiety showed that Leu7, Ile9, and Asp12 are the key elements for K-Ras(G12D) selective inhibition of KRpep-2d. The cysteine bridging was also examined to identify the stable analog of KRpep-2d under reductive conditions. As a result, the KRpep-2d analog (12) including mono-methylene bridging showed potent K-Ras(G12D) selective inhibition in both the presence and the absence of dithiothreitol. This means that mono-methylene bridging is an effective strategy to obtain a reduction-resistance analog of parent disulfide cyclic peptides. Peptide 12 inhibited proliferation of K-Ras(G12D)-driven cancer cells significantly. These results gave valuable information for further optimization of KRpep-2d to provide novel anti-cancer drug candidates targeting the K-Ras(G12D) mutant.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cyclic peptide; Cysteine bridging; K-Ras(G12D); Mono-methylene; Mutant selective

Mesh:

Substances:

Year:  2017        PMID: 28457754     DOI: 10.1016/j.bmcl.2017.04.063

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  10 in total

1.  Crystal Structure of a Human K-Ras G12D Mutant in Complex with GDP and the Cyclic Inhibitory Peptide KRpep-2d.

Authors:  Satoshi Sogabe; Yusuke Kamada; Masanori Miwa; Ayumu Niida; Tomoya Sameshima; Masahiro Kamaura; Kazuko Yonemori; Shigekazu Sasaki; Jun-Ichi Sakamoto; Kotaro Sakamoto
Journal:  ACS Med Chem Lett       Date:  2017-05-10       Impact factor: 4.345

2.  Accelerated Identification of Cell Active KRAS Inhibitory Macrocyclic Peptides using Mixture Libraries and Automated Ligand Identification System (ALIS) Technology.

Authors:  Michael Garrigou; Bérengère Sauvagnat; Ruchia Duggal; Nicole Boo; Pooja Gopal; Jennifer M Johnston; Anthony Partridge; Tomi Sawyer; Kaustav Biswas; Nicolas Boyer
Journal:  J Med Chem       Date:  2022-06-15       Impact factor: 8.039

3.  The K-Ras(G12D)-inhibitory peptide KS-58 suppresses growth of murine CT26 colorectal cancer cell-derived tumors.

Authors:  Kotaro Sakamoto; Bangzhong Lin; Kazuto Nunomura; Takeshi Izawa; Shinsaku Nakagawa
Journal:  Sci Rep       Date:  2022-05-17       Impact factor: 4.996

4.  RAS-inhibiting biologics identify and probe druggable pockets including an SII-α3 allosteric site.

Authors:  Katarzyna Z Haza; Heather L Martin; Ajinkya Rao; Amy L Turner; Sophie E Saunders; Britta Petersen; Christian Tiede; Kevin Tipping; Anna A Tang; Modupe Ajayi; Thomas Taylor; Maia Harvey; Keri M Fishwick; Thomas L Adams; Thembaninkosi G Gaule; Chi H Trinh; Matthew Johnson; Alexander L Breeze; Thomas A Edwards; Michael J McPherson; Darren C Tomlinson
Journal:  Nat Commun       Date:  2021-06-30       Impact factor: 14.919

Review 5.  Structure-based inhibitor design of mutant RAS proteins-a paradigm shift.

Authors:  Kinga Nyíri; Gergely Koppány; Beáta G Vértessy
Journal:  Cancer Metastasis Rev       Date:  2020-12       Impact factor: 9.264

6.  Generation of KS-58 as the first K-Ras(G12D)-inhibitory peptide presenting anti-cancer activity in vivo.

Authors:  Kotaro Sakamoto; Teruaki Masutani; Takatsugu Hirokawa
Journal:  Sci Rep       Date:  2020-12-10       Impact factor: 4.379

7.  Discovery of cell active macrocyclic peptides with on-target inhibition of KRAS signaling.

Authors:  Shuhui Lim; Nicolas Boyer; Nicole Boo; Chunhui Huang; Gireedhar Venkatachalam; Yu-Chi Angela Juang; Michael Garrigou; Hung Yi Kristal Kaan; Ruchia Duggal; Khong Ming Peh; Ahmad Sadruddin; Pooja Gopal; Tsz Ying Yuen; Simon Ng; Srinivasaraghavan Kannan; Christopher J Brown; Chandra S Verma; Peter Orth; Andrea Peier; Lan Ge; Xiang Yu; Bhavana Bhatt; Feifei Chen; Erjia Wang; Nianyu Jason Li; Raymond J Gonzales; Alexander Stoeck; Brian Henry; Tomi K Sawyer; David P Lane; Charles W Johannes; Kaustav Biswas; Anthony W Partridge
Journal:  Chem Sci       Date:  2021-11-25       Impact factor: 9.825

8.  KRAS is vulnerable to reversible switch-II pocket engagement in cells.

Authors:  James D Vasta; D Matthew Peacock; Qinheng Zheng; Joel A Walker; Ziyang Zhang; Chad A Zimprich; Morgan R Thomas; Michael T Beck; Brock F Binkowski; Cesear R Corona; Matthew B Robers; Kevan M Shokat
Journal:  Nat Chem Biol       Date:  2022-03-21       Impact factor: 16.174

9.  In Silico Strategies for Designing of Peptide Inhibitors of Oncogenic K-Ras G12V Mutant: Inhibiting Cancer Growth and Proliferation.

Authors:  Mehreen Ghufran; Haider Ali Khan; Mehran Ullah; Sabreen Ghufran; Muhammad Ayaz; Muhammad Siddiq; Syed Shams Ul Hassan; Simona Bungau
Journal:  Cancers (Basel)       Date:  2022-10-06       Impact factor: 6.575

10.  GTP-State-Selective Cyclic Peptide Ligands of K-Ras(G12D) Block Its Interaction with Raf.

Authors:  Ziyang Zhang; Rong Gao; Qi Hu; Hayden Peacock; D Matthew Peacock; Shizhong Dai; Kevan M Shokat; Hiroaki Suga
Journal:  ACS Cent Sci       Date:  2020-09-23       Impact factor: 14.553

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.